



Designation: F2064 – 14

Standard Guide for Characterization and Testing of Alginates as Starting Materials Intended for Use in Biomedical and Tissue Engineered Medical Product Applications¹

This standard is issued under the fixed designation F2064; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

INTRODUCTION

Alginate has found uses in a variety of products ranging from simple technical applications such as viscosifiers to advanced biomedical matrices providing controlled drug delivery from immobilized living cells. As for most hydrocolloids, the functionality of alginate is related to its chemical and structural composition. The aim of this guide is to identify key parameters relevant for the functionality and characterization of alginates for the development of new commercial applications of alginates for the biomedical and pharmaceutical industries.

1. Scope

1.1 This guide covers the evaluation of alginates suitable for use in biomedical or pharmaceutical applications, or both, including, but not limited to, Tissue Engineered Medical Products (TEMPs).

1.2 This guide addresses key parameters relevant for the functionality, characterization, and purity of alginates.

1.3 As with any material, some characteristics of alginates may be altered by processing techniques (such as molding, extrusion, machining, assembly, sterilization, and so forth) required for the production of a specific part or device. Therefore, properties of fabricated forms of this polymer should be evaluated using test methods that are appropriate to ensure safety and efficacy and are not addressed in this guide.

1.4 **Warning**—Mercury has been designated by EPA and many state agencies as a hazardous material that can cause central nervous system, kidney, and liver damage. Mercury, or its vapor, may be hazardous to health and corrosive to materials. Caution should be taken when handling mercury and mercury-containing products. See the applicable product Material Safety Data Sheet (MSDS) for details and EPA's website (<http://www.epa.gov/mercury/faq.htm>) for additional information. Users should be aware that selling mercury or mercury-containing products, or both, in your state may be prohibited by state law.

1.5 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.*

2. Referenced Documents

2.1 ASTM Standards:²

- D2196 Test Methods for Rheological Properties of Non-Newtonian Materials by Rotational Viscometer
- F619 Practice for Extraction of Medical Plastics
- F748 Practice for Selecting Generic Biological Test Methods for Materials and Devices
- F749 Practice for Evaluating Material Extracts by Intracutaneous Injection in the Rabbit
- F756 Practice for Assessment of Hemolytic Properties of Materials
- F763 Practice for Short-Term Screening of Implant Materials
- F813 Practice for Direct Contact Cell Culture Evaluation of Materials for Medical Devices
- F895 Test Method for Agar Diffusion Cell Culture Screening for Cytotoxicity
- F981 Practice for Assessment of Compatibility of Biomaterials for Surgical Implants with Respect to Effect of Materials on Muscle and Insertion into Bone
- F1251 Terminology Relating to Polymeric Biomaterials in

¹ This guide is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.42 on Biomaterials and Biomolecules for TEMP.

Current edition approved Oct. 1, 2014. Published February 2015. Originally approved in 2000. Last previous edition approved in 2000 as F2064 – 00 (2006)^{ε1}. DOI: 10.1520/F2064-14.

² For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For *Annual Book of ASTM Standards* volume information, refer to the standard's Document Summary page on the ASTM website.

- Medical and Surgical Devices (Withdrawn 2012)³
- F1439** Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials
- F1903** Practice for Testing For Biological Responses to Particles *In Vitro*
- F1904** Practice for Testing the Biological Responses to Particles *in vivo*
- F1905** Practice For Selecting Tests for Determining the Propensity of Materials to Cause Immunotoxicity (Withdrawn 2011)³
- F1906** Practice for Evaluation of Immune Responses In Biocompatibility Testing Using ELISA Tests, Lymphocyte Proliferation, and Cell Migration (Withdrawn 2011)³
- F2259** Test Method for Determining the Chemical Composition and Sequence in Alginate by Proton Nuclear Magnetic Resonance (¹H NMR) Spectroscopy
- F2315** Guide for Immobilization or Encapsulation of Living Cells or Tissue in Alginate Gels
- F2605** Test Method for Determining the Molar Mass of Sodium Alginate by Size Exclusion Chromatography with Multi-angle Light Scattering Detection (SEC-MALS)
- 2.2 *USP Document*:⁴
- USP Monograph USP 35/NF 30** Sodium Alginate
- 2.3 *ISO Documents*:⁵
- ISO 31-8** Quantities and units — Part 8: Physical chemistry and molecular physics
- ISO 10993** Biological Evaluation of Medical Devices:
- ISO 10993-1** Biological Evaluation of Medical Devices—Part 1: Evaluation and Testing
- ISO 10993-3** Part 3: Tests for Genotoxicity, Carcinogenicity and Reproductive Toxicity
- ISO 10993-9—Part 9**: Framework for Identification and Quantification of Potential Degradation Products
- ISO 10993-17—Part 17**: Methods for Establishment of Allowable Limits for Leachable Substances Using Health-Based Risk Assessment
- ISO 13408-1: 1998**: Aseptic Processing of Health Care Products—Part 1: General Requirements.
- 2.4 *ICH Documents*:⁶
- International Conference on Harmonization (ICH) S2** Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use
- International Conference on Harmonization (ICH) Q1A** ICH Harmonized Tripartite Guidance for Stability Testing of New Drug Substances and Products (2003)
- 2.5 *FDA Documents*:⁷
- FDA Interim Guidance for Human and Veterinary Drug Products and Biologicals. Kinetic LAL techniques.** DHHS, July 15, 1991

- 2.6 *ANSI Documents*:⁸
- ANSI/AAMI/ISO 11737-1: 2006** Sterilization of Medical Devices—Microbiological Methods—Part 1: Estimation of Bioburden on Product.
- ANSI/AAMI/ISO 11737-2: 1998** Sterilization of Medical Devices—Microbiological Methods—Part 2: Tests of Sterility Performed in the Validation of a Sterilization Process
- 2.7 *AAMI Documents*:⁸
- AAMI/ISO 14160—1998** Sterilization of Single-Use Medical Devices Incorporating Materials of Animal Origin—Validation and Routine Control of Sterilization by Liquid Chemical Sterilants
- AAMI ST67: 2011** Sterilization of Health Care Products—Requirements and Guidance for Selecting a Sterility Assurance Level (SAL) for Products Labeled “Sterile”
- AAMI TIR No. 19—1998** Guidance for ANSI/AAMI/ISO 10993-7: 1995, Biological Evaluation of Medical Devices—Part 7: Ethylene Oxide Sterilization Residuals
- 2.8 *National Institute of Standards and Technology*:⁹
- NIST SP811** Special Publication: Guide for the Use of the International System of Units
- 2.9 *Other Documents*:
- 21CFR184.1724** Listing of Specific Substances Affirmed as GRAS—Sodium Alginate¹⁰

3. Terminology

3.1 *Definitions of Terms Specific to This Standard*: (see also Terminology **F1251**):

3.1.1 *alginate, n*—a polysaccharide substance containing calcium, magnesium, sodium, and potassium salts obtained from some of the more common species of marine algae. Alginate exists in brown algae as the most abundant polysaccharide, mainly occurring in the cell walls and intercellular spaces of brown seaweed and kelp. Its main function is to contribute to the strength and flexibility of the seaweed plant. Alginate is classified as a hydrocolloid. The most commonly used alginate is sodium alginate.

3.1.2 *decomposition, n*—structural changes of alginates due to exposure to environmental, chemical or thermal factors, such as temperatures greater than 180°C. Decomposition can result in deleterious changes to the alginate.

3.1.3 *degradation, n*—change in the chemical structure, physical properties, or appearance of a material. Degradation of polysaccharides occurs by means of cleavage of the glycosidic bonds, usually by acid catalyzed hydrolysis. Degradation can also occur thermally. It is important to note that degradation is not synonymous with decomposition. Degradation is often used as a synonym for depolymerization when referring to polymers.

³ The last approved version of this historical standard is referenced on www.astm.org.

⁴ Available from U.S. Pharmacopeia (USP), 12601 Twinbrook Pkwy., Rockville, MD 20852.

⁵ Available from American National Standards Institute (ANSI), 25 W. 43rd St., 4th Floor, New York, NY 10036.

⁶ Available from ICH Secretariat, c/o IFPMA, 30 rue de St-Jean, P.O. Box 758, 1211 Geneva 13, Switzerland.

⁷ Available from U. S. Food and Drug Administration, 5600 Fishers Lane, Rockville MD 20857-0001.

⁸ Association for the Advancement of Medical Instrumentation 1110 North Glebe Rd., Suite 220, Arlington, VA 22201-4795.

⁹ Available from National Institute of Standards and Technology (NIST), 100 Bureau Dr., Stop 1070, Gaithersburg, MD 20899-1070, <http://physics.nist.gov/cuu/Units/bibliography.html>.

¹⁰ Available from Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402.

3.1.4 *depolymerization, n*—reduction in length of a polymer chain to form shorter polymeric units. Depolymerization may reduce the polymer chain to oligomeric or monomeric units, or both. In alginates, hydrolysis of the glycosidic bonds is the primary mechanism.

3.1.5 *Endotoxin, n*—a high-molecular weight lipopolysaccharide (LPS) complex associated with the cell wall of gram-negative bacteria that is pyrogenic in humans. Though endotoxins are pyrogens, not all pyrogens are endotoxins.

3.1.6 *G*—abbreviation for α -L-guluronic acid, one of the two monomers making up the alginate polysaccharide molecule. G-rich alginate has a greater than 50 % content of guluronate residues in the polymer chain. G-block refers to a homopolymeric block of G residues.

3.1.7 *hydrocolloid, n*—a water-soluble polymer of colloidal nature when hydrated.

3.1.8 *M*—abbreviation for β -D-mannuronic acid, one of the two monomers making up the alginate polysaccharide chain. M-rich alginate has a greater than 50% content of mannuronate residues in the polymer chain.

3.1.9 *molar mass average, n*—the given mass-average molar mass (M_w) of an alginate will always represent an average of all of the molecules in the population. The most common ways to express the M_w are as the number average (\bar{M}_n) and the weight average (\bar{M}_w). The two averages are defined by the following equations:

$$\bar{M}_n = \frac{\sum_i N_i M_i}{\sum_i N_i} \quad \text{and} \quad \bar{M}_w = \frac{\sum_i w_i M_i}{\sum_i w_i} = \frac{\sum_i N_i M_i^2}{\sum_i N_i M_i} \quad (1)$$

where:

N_i = number of molecules having a specific molar mass, M_i ,
and

w_i = mass of molecules having a specific molar mass, M_i .

In a polydisperse molecular population the relation $\bar{M}_w > \bar{M}_n$ is always valid. The coefficient \bar{M}_w/\bar{M}_n is referred to as the polydispersity index, and will typically be in the range from 1.5 to 3.0 for commercial alginates.

3.1.9.1 *Discussion*—The term molecular weight (abbreviated MS) is obsolete and should be replaced by the SI (Système Internationale) equivalent of either relative molecular mass (M_r), which reflects the dimensionless ratio of the mass of a single molecule to an atomic mass unit (see ISO 31-8), or molar mass (M), which refers to the mass of a mole of a substance and is typically expressed as grams/mole. For polymers and other macromolecules, use of the symbols M_w , M_n , and M_z continue, referring to mass-average molar mass, number-average molar mass, and z-average molar mass, respectively. For more information regarding proper utilization of SI units, see NIST SP811.

3.1.10 *pyrogen, n*—any substance that produces fever when administered parenterally.

4. Significance and Use

4.1 This guide contains a listing of those characterization parameters that are directly related to the functionality of alginate. This guide can be used as an aid in the selection and

characterization of the appropriate alginate for a particular application. This guide is intended to give guidance in the methods and types of testing necessary to properly characterize, assess, and ensure consistency in the performance of a particular alginate. It may have use in the regulation of these devices by appropriate authorities.

4.2 The alginate covered by this guide may be gelled, extruded, or otherwise formulated into biomedical devices for use in tissue-engineered medical products or drug delivery devices for implantation as determined to be appropriate, based on supporting biocompatibility and physical test data. Recommendations in this guide should not be interpreted as a guarantee of clinical success in any tissue engineered medical product or drug delivery application. Further guidance for immobilizing or encapsulating living cells or tissue in alginate gels can be found in Guide F2315.

4.3 To ensure that the material supplied satisfies requirements for use in TEMPS, several general areas of characterization should be considered. These are: identity of alginate, physical and chemical characterization and testing, impurities profile, and performance-related tests.

5. Chemical and Physical Test Methods

5.1 *Identity of Alginate*—The identity of alginates can be established by several methods including, but not limited to the following:

5.1.1 Sodium alginate monograph USP 35/NF30.

5.1.2 *Fourier Transform Infrared Spectroscopy (FT-IR)*—Almost all organic chemical compounds absorb infrared radiation at frequencies characteristic for the functional groups in the compound. A FT-IR spectrum will show absorption bands relating to bond stretching and bending and can therefore serve as a unique fingerprint of a specific compound. Identity of sodium alginate can be assessed by Fourier transform infrared spectroscopy (FT-IR).

5.1.2.1 *Alginate as a powder*—In attenuated total reflectance (ATR), an infrared beam enters a diamond crystal. Internal reflection within the crystal creates an evanescent wave. The wave continues beyond the crystal surface and into the sample that is held in close contact to the crystal surface. The penetration depth of the beam is of the order of a few microns. The beam is reflected several times within the crystal and carries spectral information from the sample into the detector. The sample is analyzed as a powder. Apply a powder sample of alginate to the FT-IR ATR crystal and follow the instrument manufacturer's procedure for recording spectra. Record the IR spectrum of the crystal without sample (CO_2 and H_2O correction), then record the IR spectrum of the sample using 4 scans at a speed of $0.2 \text{ cm}^{-1}/\text{s}$ and a resolution of 4 cm^{-1} from 4000 cm^{-1} to 650 cm^{-1} . A typical FT-IR ATR spectrum of sodium alginate is shown in Fig. 1.

5.1.2.2 *Alginate film*—Cast an alginate film from a 0.25 % (w/v) solution of sodium alginate by drying approximately 500 μL of the sample onto a disposable IR card for 3 to 4 h at 60°C . Record a background spectrum between 4000 and 400 cm^{-1} using 128 scans at a resolution of 4 cm^{-1} . Record the IR spectrum of a dried blank IR card, then record the IR spectrum of the sample using 128 scans at a resolution of 4 cm^{-1} , %




FIG. 1 Typical FT-IR ATR Spectrum of Sodium Alginate

transmission mode. Label the peaks. Typical frequencies (cm^{-1}) for sodium alginate are 3375-3390 (b), 1613 (s), 1416 (s), 1320 (w), 1125, 1089, 1031 (s), 948 (m), 903 (m), and 811 (m). The peak designators are: sh: sharp; s: strong; m: medium; w: weak; and b: broad.

5.2 Physical and chemical characterization of alginate:

5.2.1 The composition and sequential structure of alginate can be a key functional attribute of any alginate. Variations in the composition or the sequential structure, or both, may, but not necessarily, cause differences in performance of an alginate in a particular end use. This information may be determined by the following method: High-resolution ^1H and ^{13}C -nuclear magnetic resonance spectroscopy (NMR). Sodium alginate

should be dissolved in D_2O and partially degraded to a degree of depolymerization of 20 to 30 using mild acid hydrolysis before recording proton or carbon NMR spectra (Grasdalen, H., Larsen, B., and Smidsrød, O., Carbohydr. Res., 68, 23-31, 1979). Techniques have been developed to determine the monad frequencies F_G (fraction of guluronate residues) and F_M (fraction of mannuronate residues), the four nearest neighboring (diad) frequencies (F_{GG} , F_{GM} , F_{MG} , and F_{MM}) and the eight next nearest neighboring (triad) frequencies (F_{GGG} , F_{GGM} , F_{GMM} , F_{GMM} , F_{MGM} , F_{MGM} , F_{MGG} , F_{MMG} , and F_{MMM}). A typical ^1H -NMR spectrum of alginate is shown in Fig. 2. Alginate is characterized by calculating parameters such as M/G ratio, G-content, consecutive number of G monomers (that is, $G > 1$),




FIG. 2 Typical ^1H NMR of Sodium Alginate